



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/573,164	
			Filing Date	November 9, 2006	
			First Named Inventor	Enrico Colli	
			Art Unit	1612	
			Examiner Name	S. N. Qazi	
Sheet	1	of	3	Attorney Docket Number	62138US(49949)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,030,963	02-29-2000	Iacobelli et al.	
	AB	US-6,331,642	12-18-2001	Batcho et al.	
	AC	US-6,008,209	12-28-1999	Manchand et al.	
	AD	US-5,872,113	02-16-1999	Nester, Jr. et al.	
	AE	US-5,811,414	09-22-1998	Bryce et al.	
	AF	US-5,747,479	05-05-1998	Bryce et al.	
	AG	US-5,804,574	09-08-1998	Bryce et al.	
	AH	US-2002/0128240	09-12-2002	Mazess	
	AI	US-5,763,429	06-09-1998	Bishop et al.	
	AJ	US-5,795,882	08-18-1998	Bishop et al.	
	AK	US-5,939,408	08-17-1999	Batcho et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP 0 808 833	09-22-2004	Batcho et al.		
	BB	EP 1 082 298	11-05-2003	Bishop et al.		
	BC	WO 03/032961	04-24-2003	Di Salle et al.		
	BD	EP 1050537	11-05-2003	Kabat		
	BE	EP 1048661	11-02-2000	Daniewski et al.		
	BF	EP 0980354	06-19-2002	Manchand et al.		
	BG	EP 808832	04-23-2003	Manchand et al.		
	BH	WO 97/25050	07-17-1997	Bryce et al.		
	BI	EP 0654467	02-11-1998	Doran et al.		
	BJ	WO 01/30751	05-03-2001	Holick et al.		
	BK	IT 1297381	12-09-1997	Crescioli Clara		
	BL	WO- 03/034961 A1	05-01-2003			
	BM	WO- 98/29123 A1	07-09-1998			
	BN	WO- 03/047595 A1	06-12-2003			
	BO	EP- 0 808 833	11-26-1997			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	BOS2 750300.1	Date Considered	
--------------------	---------------	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,164
				Filing Date	November 9, 2006
				First Named Inventor	Enrico Colli
				Art Unit	1612
				Examiner Name	S. N. Qazi
Sheet	2	of	3	Attorney Docket Number	62138US(49949)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	C. CRESCIOLI et al. Endocrinology (2003), 144(7), 3046-3057.	
	CB	C. CRESCIOLI et al. Molecular and Cellular Endocrinology (2002), 198, 69-75.	
	CC	D. VILLARI et al. Journal of Urology (2003), 169(4) Suppl 281.	
	CD	A. KRISHNAN et al. Journal of Cellular Biochemistry (2003), 88(2), 363-371.	
	CE	C. CRESCIOLI et al. Journal of Clinical Endocrinology and Metabolism (2000), 85(7), 2576-2583.	
	CF	H. HUYNH et al. International Journal of Oncology (1998), 13(1), 137-143.	
	CG	G. SCHWARTZ et al. Cancer Epidemiology, Biomarkers and Prevention (1998), 7(5), 391-395.	
	CH	D. FELDMAN et al. Advances in Experimental Medicine and Biology (1995), 375, 53-63.	
	CI	D. KIRK. International Journal of Cancer Supplement (2002) 13, 54	
	CJ	A. ISMAIL et al. Journal of Bone and Mineral Research (2002), 17(1), S288.	
	CK	A. ISMAIL et al. Journal of Bone and Mineral Research (2001), 16(1), S429.	
	CL	S. PELEG et al. Bone (New York) (2000), 27(4) 29S.	
	CM	S. TONG et al. Journal of Bone and Mineral Research (2000), 15(1), S562.	
	CN	S. PELEG et al. Journal of Cellular Biochemistry (2003) 88(2), 267-273.	
	CO	S. PELEG et al. Endocrinology (2002), 143 (5), 1625-1636.	
	CP	M. KABAT et al. Journal of Organic Chemistry (2001), 66(18), 6141-6150.	
	CQ	M. BRANDL et al. Journal of Pharmaceutical Sciences, 92(10), 2003, 1981-1989.	
	CR	H. DALLOSSO et al. Neurourology and Urodynamics (2004) 23, 204-210.	
	CS	B. KONETY et al. Journal of Urology (2001) 165, 253-258.	
	CT	C. CRESCIOLI et al. European Journal of Endocrinology (2004) 150:591-603.	
	CU	J. HSU et al. Cancer Research (2001) 61(7):2852-2856.	
	CV	M. CAMPBELL et al. Journal of the National Cancer Institute (1997) 89(3):182-184.	
	CW	I. THOMPSON et al. New England Journal of Medicine (2003) 349(3): 215-224.	
	CX	V. KASSABIAN. The Lancet (2003) 361: 60-62.	
	CY	P. SCARDINO. New England Journal of Medicine (2003) 349(3): 297-299.	
	CAA	MEALY, N E: "BXL-268" DRUGS OF THE FUTURE 2004 SPAIN, VOL. 29, NO. 6, PAGE 629.	
	CAB	ANON: DRUG NEWS AND PERSPECTIVES, 2003, VOL. 16. NO. 2, PAGE 122.	
	CAC	Marcelli, M. et al., "Hormonal Signaling in Prostatic Hyperplasia and Neoplasia." The Journal of Clinical Endocrinology & Metabolism. 84(10): 3463-3468 (1999)	
	CAE	D. FELDMAN, et al., "Vitamin D and Prostate Cancer." Diet and Cancer; Chapter 5, pages 53-63 (1995)	
	CAF	M. MAGGI, et al., "Pre-clinical Evidence and Clinical Translation of Benign Prostatic Hyperplasia Treatment by the Vitamin D Receptor Agonist BXL-628 (Elocalcitol)." J. Endocrinol. Invest. 29: 665-674 (2006)	
	CAG	Press Release: BioXell Reports Top-Line Phase IIB Results (April 8, 2009)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	BOS2 750300.1	Date Considered	
--------------------	---------------	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,164
				Filing Date	November 9, 2006
				First Named Inventor	Enrico Colli
				Art Unit	1612
				Examiner Name	S. N. Qazi
Sheet	3	of	3	Attorney Docket Number	62138US(49949)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CAI	Report of Results of Phase IIB Trial of Elocalcitol In Patients Suffering from Overactive Bladder(OAB)	
	CAJ	Chem Abstracts File Registry No. 199798-84-0 (January 15, 1998)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	BOS2 750300.1	Date Considered	
-----------------------	---------------	--------------------	--